Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medifast (MED) EBITDA (2016 - 2025)

Medifast (MED) has disclosed EBITDA for 16 consecutive years, with -$7.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 1200.56% year-over-year to -$7.8 million, compared with a TTM value of -$14.2 million through Dec 2025, down 593.85%, and an annual FY2025 reading of -$14.2 million, down 593.85% over the prior year.
  • EBITDA was -$7.8 million for Q4 2025 at Medifast, down from -$4.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $61.4 million in Q2 2021 and bottomed at -$7.9 million in Q2 2024.
  • Average EBITDA over 5 years is $25.8 million, with a median of $29.1 million recorded in 2022.
  • The sharpest move saw EBITDA skyrocketed 124.36% in 2021, then crashed 1200.56% in 2025.
  • Year by year, EBITDA stood at $46.8 million in 2021, then plummeted by 30.4% to $32.6 million in 2022, then tumbled by 73.39% to $8.7 million in 2023, then tumbled by 91.83% to $709000.0 in 2024, then plummeted by 1200.56% to -$7.8 million in 2025.
  • Business Quant data shows EBITDA for MED at -$7.8 million in Q4 2025, -$4.1 million in Q3 2025, and -$1.1 million in Q2 2025.